BioSpecifics Technologies Corp. engages in the development of an injectable collagenase clostridium histolyticum for multiple indications. It sells its products under the brand XIAFLEX. The company was founded in 1990 and is headquartered in Lynbrook, NY.
Company profile
Ticker
BSTC
Exchange
Website
CEO
Joseph Truitt
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Advance Biofactures Corp. ...
IRS number
113054851
BSTC stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
22 Dec 20
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Dec 20
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Dec 20
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Dec 20
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Dec 20
RW
Registration withdrawal request
2 Dec 20
8-K
BioSpecifics Announces Completion of Acquisition by Endo Pharmaceuticals
2 Dec 20
SC 14D9/A
Tender offer solicitation (amended)
2 Dec 20
SC TO-T/A
Third party tender offer statement (amended)
2 Dec 20
25-NSE
Exchange delisting
2 Dec 20
Latest ownership filings
SC 13G/A
RICE HALL JAMES & ASSOCIATES, LLC
16 Feb 21
SC 13G/A
RENAISSANCE TECHNOLOGIES LLC
10 Feb 21
4
Change in insider ownership
8 Dec 20
SC 13D/A
Endo International plc
4 Dec 20
4
Jennifer M Chao
2 Dec 20
4
Toby Wegman
2 Dec 20
4
Corey N. Fishman
2 Dec 20
4
Mark N Wegman
2 Dec 20
4
Michael Schamroth
2 Dec 20
4
Joseph Truitt
2 Dec 20
Financial summary
Quarter (USD) | Sep 20 | Jun 20 | Mar 20 | Sep 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.87 mm | 2.87 mm | 2.87 mm | 2.87 mm | 2.87 mm | 2.87 mm |
Cash burn (monthly) | 4.67 mm | 924.90 k | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 200.18 mm | 39.68 mm | n/a | n/a | n/a | n/a |
Cash remaining | -197.30 mm | -36.81 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | -42.3 | -39.8 | n/a | n/a | n/a | n/a |
Institutional ownership, Q1 2023
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 100.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
ENDPQ Endo International | 100.00 | $0.00 |